Routine biochemical and hematological tests have been reported to be useful in the stratification and prognostication of pediatric and adult patients with diagnosed coronavirus disease (COVID-19), correlating with poor outcomes such as the need for mechanical ventilation or intensive care, progression to multisystem organ failure, and/or death. While these tests are already well established in most clinical laboratories, there is still debate regarding their clinical value in the management of COVID-19, particularly in pediatrics, as well as the value of composite clinical risk scores in COVID-19 prognostication. This document by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on COVID-19 provides interim guidance on: (A) clinical indications for testing, (B) recommendations for test selection and interpretation, (C) considerations in test interpretation, and (D) current limitations of biochemical/hematological monitoring of COVID-19 patients. These evidence-based recommendations will provide practical guidance to clinical laboratories worldwide, underscoring the contribution of biochemical and hematological testing to our collective pandemic response.

IFCC interim guidelines on biochemical/hematological monitoring of COVID-19 patients / Thompson, Simon; Bohn, Mary Kathryn; Mancini, Nicasio; Loh, Tze Ping; Wang, Cheng-Bin; Grimmler, Matthias; Yuen, Kwok-Yung; Mueller, Robert; Koch, David; Sethi, Sunil; Rawlinson, William D; Clementi, Massimo; Erasmus, Rajiv; Leportier, Marc; Kwon, Gye Cheol; Menezes, María Elizabeth; Patru, Maria-Magdalena; Gramegna, Maurizio; Singh, Krishna; Najjar, Osama; Ferrari, Maurizio; Lippi, Giuseppe; Adeli, Khosrow; Horvath, Andrea. - In: CLINICAL CHEMISTRY AND LABORATORY MEDICINE. - ISSN 1437-4331. - 0:0(2020). [Epub ahead of print] [10.1515/cclm-2020-1414]

IFCC interim guidelines on biochemical/hematological monitoring of COVID-19 patients

Mancini, Nicasio;Clementi, Massimo;Ferrari, Maurizio;
2020-01-01

Abstract

Routine biochemical and hematological tests have been reported to be useful in the stratification and prognostication of pediatric and adult patients with diagnosed coronavirus disease (COVID-19), correlating with poor outcomes such as the need for mechanical ventilation or intensive care, progression to multisystem organ failure, and/or death. While these tests are already well established in most clinical laboratories, there is still debate regarding their clinical value in the management of COVID-19, particularly in pediatrics, as well as the value of composite clinical risk scores in COVID-19 prognostication. This document by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on COVID-19 provides interim guidance on: (A) clinical indications for testing, (B) recommendations for test selection and interpretation, (C) considerations in test interpretation, and (D) current limitations of biochemical/hematological monitoring of COVID-19 patients. These evidence-based recommendations will provide practical guidance to clinical laboratories worldwide, underscoring the contribution of biochemical and hematological testing to our collective pandemic response.
2020
COVID-19
SARS-CoV-2
biochemistry
hematology
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/105359
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 23
social impact